You are here

Bluebird Bio

JPM: Bluebird to spin off cancer therapies into new company

JPM: Bluebird to spin off cancer therapies into new company

Fierce Biotech

Flag link:

10 Biopharma Stories to Look Forward to in 2021

10 Biopharma Stories to Look Forward to in 2021

BioSpace

venture capital

TG Therapeutics

Flag link:

3 FDA Dates Biotech Investors Should Circle in 2021

3 FDA Dates Biotech Investors Should Circle in 2021

Motley Fool

Multiple Myeloma

Alzheimer's disease

targeted therapeutics

maringal zone lymphoma

Flag link:

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

Pharmaforum

beta-thalassemia

Flag link:

FDA gene therapy holdups suggest closer scrutiny by agency

FDA gene therapy holdups suggest closer scrutiny by agency

BioPharma Dive

Sarepta Therapeutics

Voyager Therapeutics

Flag link:

Can bluebird bio Recover From Another Major Setback?

Can bluebird bio Recover From Another Major Setback?

Motley Fool

sickle cell disease

Flag link:

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

Endpoints

sickle cell disease

Flag link:

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

Fierce Biotech

Bristol-Myers Squibb

priority review

Flag link:

Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout

Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout

BioPharma Dive

Bristol-Myers Squibb

Multiple Myeloma

Flag link:

New CRISPR, gene therapy results strengthen potential for treatment of blood diseases

New CRISPR, gene therapy results strengthen potential for treatment of blood diseases

BioPharma Dive

beta thalassemia

sickle cell disease

CRISPR Therapeutics

Flag link:

EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder

EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder

EP Vantage

sickle cell disease

Flag link:

What Sanofi Might Buy With Its Regeneron Windfall

What Sanofi Might Buy With Its Regeneron Windfall

Barron's

Flag link:

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

Motley Fool

beta thalassemia

clinical trials

Flag link:

Biotech companies raise cash as coronavirus updates lift stocks

Biotech companies raise cash as coronavirus updates lift stocks

BioPharma Dive

Moderna Therapeutics

Turning Point Therapeutics

Krystal Biotech

Clovis Oncology

Flag link:

Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials

Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials

BioSpace

Bristol-Myers Squibb

non-small cell lung cancer

Multiple Myeloma

Flag link:

Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline

Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline

Motley Fool

Bristol-Myers Squibb

refusal to file letter

Flag link:

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

Motley Fool

Bristol-Myers Squibb

Flag link:

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Endpoints

Bristol-Meyers Squibb

Flag link:

Bluebird says gene therapy application delayed again, citing disagreement with FDA

Bluebird says gene therapy application delayed again, citing disagreement with FDA

BioPharma Dive

Flag link:

Pages